The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Featured:
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of elotuzumab (E) in combination with pomalidomide (P) and low-dose dexamethasone (d, EPd) for patients with relapsed/refractory multiple myeloma (RRMM).1,2
The recommendation is for the treatment of patients who have received ≥ two prior lines of therapy, including lenalidomide and a proteasome inhibitor (PI), and who progressed with their last therapy.1 This is based on the ELOQUENT-3 study, which showed EPd reduced the risk of progression or death by 46% compared with Pd in patients with RRMM.3
Elotuzumab was originally approved by the EMA in combination with lenalidomide and dexamethasone for patients with RRMM who received at least one prior line of therapy.4 The United States (US) Food & Drug Administration (FDA) have already approved the EPd triplet in patients with RRMM in November 2018.5
Elotuzumab specifically targets the signaling lymphocyte activation molecule family member 7 (SLAMF7) which is a cell surface glycoprotein expressed on MM cells as well as natural killer (NK) cells, plasma cells, and in low-levels on other hematopoietic cells. Therefore, elotuzumab has a dual mechanism of action:
Elotuzumab is administered as an intravenous (IV) injection.
ELOQUENT-3 (NCT02654132) is a randomized, open-label, phase II trial, of EPd versus Pd in patients with RRMM. The results of the ELOQUENT-3 trial were presented by Professor Meletios A. Dimopoulos at the European Hematology Association (EHA) congress in June 2018.3
In the trial, EPd doubled the median PFS and ORR compared to Pd (Table 1). Whilst survival data was not mature, there was a positive trend for EPd compared to Pd. Safety data showed the EPd regimen was well-tolerated (Table 2) and a low rate of infusion-related reactions in the EPd arm (3.3%).
Table 1. Efficacy data from ELOQUENT-3 trial2,6
* Minimum follow-up of 9.1 months. EPd, elotuzumab, pomalidomide and dexamethasone; HR, hazard ratio; NE,, not estimable; OR, odds ratio; ORR, overall response rate; PFS, progression free survival; |
||||
|
EPd (n=60) |
Pd (n=57) |
Statistics |
p value |
---|---|---|---|---|
Median PFS*
|
10.25 months 95% CI 5.59 NE |
4.67 months 95% CI 2.83–7.16 |
HR 0.54 95% CI 0.34–0.86 |
0.0078 |
ORR |
53.3% 95% CI 40.0–66.3 |
26.3% 95% CI 15.5–39.7 |
OR 3.25 95% CI 1.49–7.11 |
0.0029 |
Table 2. Safety data from the ELOQUENT-3 trial2,6
* with a ≥10% incidence in EPd arm, and ≥5% incidence in Pd arm. EPd, elotuzumab, pomalidomide and dexamethasone; SAEs, serious adverse events | ||
|
EPd (n=60) |
Pd (n=55) |
---|---|---|
SAEs |
22% |
15% |
Most common SAEs |
||
Pneumonia |
13% |
11% |
Respiratory tract infection |
7% |
3.6% |
AEs* |
||
Constipation |
22% |
11% |
Hyperglycemia |
20% |
15% |
Pneumonia |
18% |
13% |
Diarrhea |
18% |
9% |
Respiratory tract infection |
17% |
9% |
Bone pain |
15% |
9% |
Dyspnea |
15% |
7% |
Muscle spasms |
13% |
5% |
Peripheral edema |
13% |
7% |
Lymphopenia |
10% |
1.8% |
"This combination was very well tolerated and maybe the treatment of choice for elderly patients for whom carfilzomib-based therapies maybe contraindicated. The trend for survival advantage is very encouraging."
References